Sinphar Pharmaceutical Co (TPE:1734) Ending Cash Position: NT$1,477 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1734 Sinphar Pharmaceutical Co Ltd TPE:1734
82 GF Score
Price NT$30.60
GF Value NT$29.90
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Sinphar Pharmaceutical Co Ending Cash Position?

Sinphar Pharmaceutical Co TPE:1734 82 Ending Cash Position is NT$1,477 Mil as of Jun. 2026. GuruFocus rates TPE:1734 with a GF Score™ of 82/100 and a GF Value™ of NT$29.90 (Fairly Valued). The stock has 4 warning signs investors should review.

Sinphar Pharmaceutical Co's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$1,477 Mil.

Sinphar Pharmaceutical Co's quarterly Ending Cash Position increased from Dec. 2025 (NT$864 Mil) to Mar. 2026 (NT$1,092 Mil) and increased from Mar. 2026 (NT$1,092 Mil) to Jun. 2026 (NT$1,477 Mil).

Sinphar Pharmaceutical Co's annual Ending Cash Position increased from Dec. 2023 (NT$1,074 Mil) to Dec. 2024 (NT$1,076 Mil) but then declined from Dec. 2024 (NT$1,076 Mil) to Dec. 2025 (NT$864 Mil).

Sinphar Pharmaceutical Co Ending Cash Position Related Terms

Sinphar Pharmaceutical Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sinphar Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinphar Pharmaceutical Co Ending Cash Position Chart

Sinphar Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,194.79 1,237.56 1,074.49 1,075.67 864.14

Sinphar Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 890.70 895.16 864.14 1,091.74 1,476.85
TPE:1734
82GF Score
Sinphar Pharmaceutical Co Ltd TPE:1734
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinphar Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sinphar Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1075.672+-211.533
=864

Sinphar Pharmaceutical Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1091.742+385.104
=1,477

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$1,477 Mil mean?
Sinphar Pharmaceutical Co (TPE:1734) has a Ending Cash Position of NT$1,477 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sinphar Pharmaceutical Co and its competitors.
Is Sinphar Pharmaceutical Co's Ending Cash Position too high?
Sinphar Pharmaceutical Co's current Ending Cash Position is NT$1,477 Mil. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Ending Cash Position compare to VRTX and REGN?
Sinphar Pharmaceutical Co's Ending Cash Position of NT$1,477 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sinphar Pharmaceutical Co and its competitors. Sinphar Pharmaceutical Co's current Ending Cash Position is NT$1,477 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.90, compared to a current price of NT$30.60 — trading 2.3% above its estimated fair value. The current Ending Cash Position is NT$1,477 Mil. Sinphar Pharmaceutical Co's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Ending Cash Position is NT$1,477 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?

Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be overvalued. The current stock price of NT$30.60 is trading 2.3% above its estimated GF Value™ of NT$29.90. GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TPE:1734:

  • Ending Cash Position: NT$1,477 Mil
  • GF Value™: NT$29.90 vs. price of NT$30.60 (2.3% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinphar Pharmaceutical Co Business Description

Address No.84, Zhongshan Road, Dongshan Township, Zhongshan Village, Yilan, TWN, 269
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
82GF Score

Get the complete analysis for TPE:1734

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.60
Price
NT$29.90
GF Value